Jun 18 |
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
|
Jun 1 |
Immunocore says new data demonstrates Kimmtrak efficacy for uveal melanoma
|
Jun 1 |
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
|
May 31 |
Immunocore touts updated phase 1 results for melanoma asset brenetafusp
|
May 31 |
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
|
May 30 |
Immunocore to present at the Jefferies Global Healthcare Conference
|
May 29 |
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
|
May 24 |
Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.
|
May 11 |
Analysts Have Made A Financial Statement On Immunocore Holdings plc's (NASDAQ:IMCR) First-Quarter Report
|
May 8 |
Immunocore GAAP EPS of -$0.49 misses by $0.13, revenue of $70.5M beats by $1.32M
|